Abstract
In order to better understand the binding mode of hydroxamic acid derivatives as urease inhibitors, 3D-QSAR and molecular docking studies were conducted on a set of twenty seven urease inhibitors. The 3D-QSAR models demonstrated good ability to predict the activity of studied compounds after performing a leave-one-out (LOO) cross-validation (q2 = 0.848, 0.755) and (r2 = 0.978, 0.984) for the CoMFA and CoMSIA models, respectively. The predictive ability and robustness of the models were validated by a test set compounds and docking simulation.
Keywords: CoMFA, CoMSIA, Docking, Urease, Leave-one-out, Hydroxamic Acid
Letters in Drug Design & Discovery
Title: Prediction of Binding Affinities for Hydroxamic Acid Derivatives as Urease Inhibitors by Molecular Docking and 3D-QSAR Studies
Volume: 6 Issue: 2
Author(s): Zaheer-ul-Haq and Abdul Wadood
Affiliation:
Keywords: CoMFA, CoMSIA, Docking, Urease, Leave-one-out, Hydroxamic Acid
Abstract: In order to better understand the binding mode of hydroxamic acid derivatives as urease inhibitors, 3D-QSAR and molecular docking studies were conducted on a set of twenty seven urease inhibitors. The 3D-QSAR models demonstrated good ability to predict the activity of studied compounds after performing a leave-one-out (LOO) cross-validation (q2 = 0.848, 0.755) and (r2 = 0.978, 0.984) for the CoMFA and CoMSIA models, respectively. The predictive ability and robustness of the models were validated by a test set compounds and docking simulation.
Export Options
About this article
Cite this article as:
Zaheer-ul-Haq and Wadood Abdul, Prediction of Binding Affinities for Hydroxamic Acid Derivatives as Urease Inhibitors by Molecular Docking and 3D-QSAR Studies, Letters in Drug Design & Discovery 2009; 6 (2) . https://dx.doi.org/10.2174/157018009787582598
DOI https://dx.doi.org/10.2174/157018009787582598 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
XMT-1001, A Novel Biodegradable Polyacetal Polymer Conjugate of Camptothecin in Clinical Development
Current Bioactive Compounds The Ambidextrous Cyclooxygenase: An Enduring Target
Inflammation & Allergy - Drug Targets (Discontinued) Chitosan Applications on Pharmaceutical Sciences: A Review
Drug Delivery Letters Medicinal Importance of Flavonoid “Eupatorin” in the Health Sectors: Therapeutic Benefit and Pharmacological Activities Through Scientific Data Analysis
Current Chinese Science Anticancer Activity of New Haloalkyl Camptothecin Esters against Human Cancer Cell Lines and Human Tumor Xenografts Grown in Nude Mice
Anti-Cancer Agents in Medicinal Chemistry Triple Negative Breast Cancer - BCL2 in Prognosis and Prediction. Review
Current Drug Targets Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery Overactive Bladder - Current Treatment Modalities
Current Women`s Health Reviews FXR, A Therapeutic Target for Bile Acid and Lipid Disorders
Mini-Reviews in Medicinal Chemistry Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?
Current Pharmacogenomics Review of the Biological Activity of Maslinic Acid
Current Drug Targets Biodegradable Black Phosphorus-based Nanomaterials in Biomedicine: Theranostic Applications
Current Medicinal Chemistry Determination of Phytochemicals by GC-MS in Two Fractions (17 and 21) of Methanol Extract of Loranthus Micranthus and their Antioxidant and Anti-Inflammatory Activity
The Natural Products Journal Molecular Dynamics in Esophageal Adenocarcinoma: Who’s in Control?
Current Cancer Drug Targets Targeting Inflammatory Bowel Diseases by Nanocarriers Loaded with Small and Biopharmaceutical Anti-Inflammatory Drugs
Current Pharmaceutical Design AGE-RAGE System and Carcinogenesis
Current Pharmaceutical Design Low-Cost Anti-HIV Compounds: Potential Application for AIDS Therapy in Developing Countries
Current Pharmaceutical Design A Review on Defects of Dendritic Cells in Common Variable Immunodeficiency
Endocrine, Metabolic & Immune Disorders - Drug Targets Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols
Current Pharmaceutical Design